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Abstract
Introduction: Rheumatoid arthritis (RA) is associated with hypogalactosylation of immunoglobulin G (IgG). We
examined whether a proxy measure for galactosylation of IgG N-glycans could predict response to therapy or was
differentially affected by methotrexate (MTX) or TNF blockade.
Methods: Using a previously defined normal phase high-performance liquid chromatography approach, we
ascertained the galactosylation status of whole serum N-glycans in two well-defined RA clinical cohorts: the
Autoimmune Biomarkers Collaborative Network (n = 98) and Nested I (n = 64). The ratio of agalactosylated to
monogalactosylated N-glycans in serum (sG0/G1) was determined before and during therapy with MTX or TNF
inhibition and correlated with anticitrullinated peptide antibody (ACPA) status and clinical response as assessed by
28-joint Disease Activity Score utilizing C-reactive peptide and European League Against Rheumatism response
criteria.
Results: RA patients from both cohorts exhibited elevation of sG0/G1 at baseline. Improvement in clinical scores
correlated with a reduction in sG0/G1 (Spearman’s r = 0.31 to 0.37; P < 0.05 for each cohort). However,
pretreatment sG0/G1 was not predictive of clinical response. Changes in sG0/G1 were similar in the MTX and TNF
inhibitor groups. Corrected for disease activity, ACPA positivity correlated with higher sG0/G1.
Conclusions: Baseline serum N-glycan hypogalactosylation, an index previously correlated with hypogalactosylation
of IgG N-glycans, did not distinguish patients with rheumatoid arthritis who were likely to experience a favorable
clinical response to MTX or TNF blockade. Clinical improvement was associated with partial glycan normalization.
ACPA-positive patients demonstrated enhanced N-glycan aberrancy compared with ACPA-negative patients.
Introduction
Human immunoglobulin G (IgG) is a glycoprotein with
a biantennary (that is, two-armed) oligosaccharide
attached to a canonical asparagine (N) in each heavy
chain. These N-glycans are unusual because they do not
decorate the protein surface. Instead, they are largely
enclosed within the Fc region, where they help to main-
tain its spatial conformation. Variations in glycan struc-
ture “fine-tune” the effector activity of the antibody,
modulating its capacity to fix complement and engage
Fc receptors [1,2]. Certain Fc glycan variants enriched
for terminal sialic acid render IgG overtly anti-inflam-
matory, accounting in part for the action of high-dose
intravenous Ig [3,4].
Interestingly, rheumatoid arthritis (RA) is characterized
by alterations in IgG glycosylation [5-8]. Patients with RA
exhibit an elevated proportion of IgG in which neither of
the two glycan arms bears a terminal galactose (thus
termed “G0”). This conformation enables binding of man-
nose-binding lectin, resulting in an enhanced propensity
to fix complement, and animal studies suggest that G0
IgG may be especially arthritogenic [9-11]. Recently, we
and others have confirmed this hypogalactosyl phenotype
in large cohorts, demonstrating additionally that change in
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IgG glycosylation predates the diagnosis of RA by an aver-
age of more than 3 years, is enriched in antibodies directed
against citrullinated peptides (ACPAs) and correlates with
disease activity [12-16]. Thus multiple lines of evidence
point to a role for IgG glycans in the pathogenesis of RA.
Although RA patients as a group exhibit altered IgG
glycans, there remains substantial heterogeneity within
this population [15]. We wished to understand whether
pretreatment glycan status could predict response to
therapy and whether disease-modifying antirheumatic
drugs (DMARDs) might affect glycans differently, poten-
tially hinting at an unexplored mode of action. Further-
more, we wished to determine whether ACPA positivity
correlated with IgG glycoform aberrancy. We therefore
performed an analysis of whole-serum N-glycan galacto-
sylation, previously noted to correlate highly with galac-
tosylation of IgG N-glycans [15,17], on serial samples
collected prospectively from patients with RA before and
after treatment with MTX and anti-TNF agents.
Materials and methods
Patients
Patient samples were obtained from two cohorts, both
of which have previously been described in detail
[18,19]. The Autoimmune Biomarkers Collaborative
Network (ABCoN) enrolled RA patients with at least six
swollen joints who received 10 mg or less of prednisone
at the initiation of TNF inhibitor therapy. Nested I
employed identical entry criteria at the initiation of ther-
apy with either MTX or a TNF inhibitor. The patients
were allowed to add an additional agent after 6 weeks.
Approximately 60% of TNF starters in each cohort
received concomitant MTX at a stable dose. In both
cohorts, serum samples were collected at baseline and 3
months after initiation of treatment. In Nested I, serum
was also collected after 2 weeks. Disease activity was
assessed using the 28-joint Disease Activity Score using
CRP (DAS28-CRP) at baseline and at 3 months. ACPA
status was assessed using the QUANTA Lite CCP IgG
ELISA kit, version 2 (a second-generation ACPA assay,
INOVA Diagnostics, Inc, San Diego, CA, USA). ABCoN
and Nested I patients provided their written informed
consent for sample acquisition. Healthy adult control
samples were obtained from deidentified blood donors
as described previously [15]. All samples were acquired
with the approval of the respective institutional review
boards.
Glycan characterization
Glycans were analyzed as described in detail previously
[15,17]. Briefly, N-glycans were liberated enzymatically
from 5 μl of whole serum, labeled and analyzed by nor-
mal-phase high-performance liquid chromatography
(NP-HPLC), which provides precise relative quantitation
of molecular species separated by size and charge. The
area under the glycan elution peaks was calculated, and
G0 was normalized to the monogalactosylated (G1) frac-
tion, which remains relatively constant across the popula-
tion [20,21]. Because the majority of neutral biantennary
glycans in serum are derived from IgG, the ratio of aga-
lactosylated to monogalactosylated N-glycans in serum
(sG0/G1) has been employed as a proxy for IgG G0/G1
(R2 = 0.83) [15,17].
Statistical analysis
Population means were compared using Student’s t-test
(two-tailed), paired or unpaired as appropriate. Correla-
tions between change in sG0/G1 and DAS28-CRP were
assessed by Spearman’s r coefficients. Statistical analyses
were performed using GraphPad Prism version 4.0 soft-
ware (GraphPad Software, Inc, La Jolla, CA, USA) or
SAS version 9.2 software (SAS Institute, Cary, NC,
USA).
Results
sG0/G1 glycan ratio is altered at baseline and improves
with treatment
Glycan profiling was performed on the sera of 98 ABCoN
patients, 64 Nested I patients and 102 matched controls
(Table 1). In the ABCoN cohort, patient therapy was
initiated with a TNF inhibitor (42 etanercept, 32 inflixi-
mab and 24 adalimumab). In the Nested I cohort, 34
patients received anti-TNF therapy (26 etanercept,
1 infliximab and 7 adalimumab) and 30 patients received
MTX. Clinical severity assessed 3 months after recruit-
ment declined in both cohorts, with mean (± SD)
DAS28-CRP scores declining from 5.16 ± 0.95 to 3.72 ±
1.33 in the ABCoN group (P < 0.0001) and from 5.62 ±
0.91 to 3.82 ± 1.55 in the Nested I group (P < 0.0001). As
expected, sG0/G1 ratios were high at baseline and
declined after 3 months of therapy, though they remained
abnormal (Figure 1). Reduction in sG0/G1 ratios paral-
leled clinical improvement, as demonstrated by the corre-
lation between the changes in sG0/G1 and DAS28-CRP
in both cohorts (Figure 2).
Serum N-glycan hypogalactosylation is not a predictor of
response to treatment
Because reliable predictors of response to therapy remain
elusive, we examined whether baseline sG0/G1 status
correlated with clinical improvement upon treatment.
For this analysis, we stratified patients after 3 months of
therapy into good responders (GRs), moderate respon-
ders (MRs) and nonresponders (NRs) according to
European League Against Rheumatism response criteria
[22]. No differences in baseline sG0/G1 ratio were
observed (Figure 3). Using the Nested I data at 2 weeks,
we further considered whether early changes in sG0/G1
Ercan et al. Arthritis Research & Therapy 2012, 14:R43
http://arthritis-research.com/content/14/2/R43
Page 2 of 8
might predict response to therapy at 3 months, sparing
patients from unnecessary exposure to expensive and
potentially toxic therapy. However, similar nonsignificant
declines in sG0/G1 were observed in all groups. The
mean changes (SD) were -0.11 (0.27) for GRs, -0.23
(0.50) for MRs and -0.11 (0.15) for NRs. Acknowledging
the caveat that the half-life of IgG is approximately 23
days [23], such that an analysis at 2 weeks might be too
soon to note substantial changes, we found no suggestion
that change in sG0/G1 could be used as an early marker
of therapeutic efficacy.
Effect of therapy with TNF inhibition or methotrexate on
sG0/G1
If hypogalactosylated IgG is pathogenic, then IgG glyco-
sylation might represent an unrecognized target of
DMARD therapy. Two of the most commonly used
therapies for RA are MTX and TNF inhibition. These
classes of agents are therapeutically complementary and
attain their efficacy via complex and incompletely under-
stood pathways. Human B cells express several different
receptors for adenosine, an anti-inflammatory mediator
implicated in the mechanism of action of MTX [24,25].
Table 1 Patients analyzeda
Patient characteristics ABCoN (N = 98) Nested I (N = 64) Control (N = 102)
Mean (SD) age, years 54.8 (12.8) 52.6 (13.3) 55.9 (13.0)
Sex (female), n (%) 75 (78)b 53 (83) 77.4
Mean (SD) disease duration, years 10.3 (9.0) 9.2 (11.6)b NA
Mean (SD) disease activity, DAS28 score 5.16 (0.95) 5.62 (0.91) NA
RF-positive, n (%) 81 (87.1) 45 (70.3)b NA
ACPA-positive, n (%) 75 (80.5) 37 (74.0)b NA
Mean (SD) sG0/G1 1.37 (0.42) 1.38 (0.41) 1.02 (0.25)
a ABCoN, Autoimmune Biomarkers Collaborative Network; ACPA, Anti-Citrullinate Peptide Antibody; DAS28, 28-joint Disease Activity Score; RF, rheumatoid factor;
sG0/G1, ratio of agalactosylated to monogalactosylated N-glycans in serum. bFractions represent proportions within available data. ABCoN gender data available
in 96 patients; Nested I, disease duration available in 62 patients, RF in 63 and ACPA in 50 patients.
















**                  *
Figure 1 Ratio of agalactosylated to monogalactosylated N-glycans in serum immunoglobulin (sIgG0/G1) is elevated at baseline and
improves with treatment. Data show sG0/G1 from baseline and follow-up visits in both cohorts. All rheumatoid arthritis time points P < 0.001
vs healthy controls. P-values were derived from paired t-tests (*P < 0.05; **P = 0.01). Paired data available for Autoimmune Biomarkers
Collaborative Network were n = 75 vs 3 months; Nested I, n = 61 vs 2 weeks and n = 48 vs 3 months.
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B cells also express receptors for TNF, and treatment of
RA with TNF inhibitors has been shown to result in dis-
ruption of germinal centers [26,27]. No data are available
on the impact of either pathway on IgG glycosylation.
We considered the possibility that either MTX or TNF
inhibition might exert an anti-inflammatory effect in part
via modulation of IgG glycans, rendering autoantibodies
less pathogenic. We therefore examined total serum N-
glycan patterns in patients receiving these therapies to
ascertain whether the correlation between clinical
improvement (change in DAS-CRP) and improvement in
sG0/G1 differed between agents. However, no such dif-
ference was noted (Figure 4).
Anticitrullinated peptide antibody status as a predictor of
sG0/G1
Several groups have shown that ACPA IgG may exhibit
unusually low levels of N-galactosylation [15,16]. To
date, however, no association between ACPA status and
level of total IgG galactosylation has been defined. Recog-
nizing that sG0/G1 varies with disease activity, we
assessed the relationship between ACPA status (positive
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Figure 2 Correlation between changes in ratio of agalactosylated to monogalactosylated N-glycans in serum (sG0/G1) and 28-joint
Disease Activity Score utilizing C-reactive peptide. Differences reported are between baseline and 3-month visits. Each point represents an
individual patient. Plots at right depict improvement (decrease) in Disease Activity Score (DAS) comparing patients in whom the sG0/G1 either
increased or decreased appreciably (> 0.1 U) over the interval studied. (A) Autoimmune Biomarkers Collaborative Network (ABCoN). (B) Nested I.
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or negative) and aberrant sG0/G1 corrected for DAS28-
CRP. In pooled baseline data from ABCoN and Nested I,
we were able to establish a significant association
between ACPA positivity and higher sG0/G1 values (P =
0.003). Pooled analysis with our recently published
cohort of 292 RA patients [15] strengthened this associa-
tion (P < 0.0006).
Discussion
Abnormal glycosylation of IgG is a well-established pheno-
type in RA, yet its clinical relevance is uncertain. In this
study, we employed a proxy measurement for IgG galacto-
sylation to address two key questions within the glycobiol-
ogy of RA: (1) whether IgG glycan aberrancy predicts
response to treatment and (2) whether DMARDs exert dif-
ferential impacts upon IgG glycosylation, thereby poten-
tially contributing to their clinical effectiveness. Using a
well-characterized high-throughput NP-HPLC technique,
we examined total serum N-glycans in two cohorts of RA
patients for whom serial blood samples and prospectively
collected clinical data were available. Because most bian-
tennary serum N-glycans originate from IgG, our data
support prior work indicating that IgG is hypogalactosy-
lated in patients with RA and that a direct correlation
between clinical and glycan improvement can be observed
at the level of the individual patient. However, we found
no evidence that (1) baseline sG0/G1 or change in sG0/G1
two weeks after initiation of treatment could predict thera-
peutic response to TNF inhibition or MTX or (2) these
agents differentially influenced N-glycan galactosylation.
The latter result suggests either that these agents exert
similar effects on IgG glycans or, perhaps more likely, that
altered IgG galactosylation arises via another route in
patients experiencing clinical improvement.
By contrast, herein we show for the first time a clear
correlation between ACPA positivity and abnormal galac-
tosylation. This correlation had not previously been
observed, likely because of confounding by differential
disease activity. Our result therefore corroborates the
observation of several groups that IgG ACPAs may exhi-
bit glycosylation that is more aberrant than that of the
IgG pool as a whole [15,16].
These results highlight gaps in the understanding of


















Figure 3 Ratio of agalactosylated to monogalactosylated N-glycans in serum (sG0/G1) does not predict therapeutic response. Baseline
sG0/G1 stratified according to European League Against Rheumatism (EULAR) response category at 3 months polled from both Autoimmune
Biomarkers Collaborative Network and Nested I cohorts. Mean ± SD for good responders 1.29 ± 0.35, moderate 1.35 ± 0.35, nonresponders 1.28
± 0.44. P = ns for all comparisons.
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reflects multiple factors, perhaps most directly the cellu-
lar complement of specific enzymes that catalyze each
step in glycan assembly [28-30]. Patients with RA show
reduced peripheral blood B-cell galactosyltransferase
activity, though the biological basis for this difference
and its relevance for IgG production by plasma cells has
not been defined [31-33]. How disease activity is asso-
ciated with altered glycosylation, why this relationship
differs from patient to patient (see, for example, Figure 2)
and how antibodies of different specificities can display
distinct glycan profiles remain to be defined. In this con-
text, recent work illustrating particular glycan aberrancy
of ACPAs from synovial fluid is of interest because it
suggests that hypogalactosylated IgG may be generated
directly within the rheumatoid synovium, accounting
perhaps for the decline of sG0/G1 as this microenviron-
ment normalizes with treatment [16].
Our study has several limitations. As noted in the
Materials and methods section, the sG0/G1 index pro-
vides an imperfect estimate of IgG G0/G1. We cannot
exclude the possibility that some of the changes observed
reflect serum glycoproteins beyond IgG, though we are
reassured in this respect by the work of other authors
who have observed similar changes in IgG purified from
RA patients [12-14]. In particular, because IgG is the
major serum source of G0 and G1 glycans, we doubt that
we would have missed a clinically important predictive
role of IgG galactosylation while using our assessment
technique, though formal confirmation of this conclusion
would require analysis of purified IgG.
Furthermore, we recognize that our method captures
only part of the complexity of IgG Fc glycans. In addition
to galactosylation, IgG glycans can vary in core fucosyla-
tion, the presence of an additional N-acetylglucosamine
bisecting the two glycan arms and the extent of terminal
sialylation. Each of these variants can have functional
implications, modulating the ability to fix complement,
engage Fc receptors and serve as a ligand for the myeloid
lectin receptor dendritic cell-specific intercellular adhe-
sion molecule 3-grabbing nonintegrin, or DC-SIGN [1,2].
Therefore, our data do not exclude the possibility that
further examination of individual IgG glycoforms,










Figure 4 Change in ratio of agalactosylated to monogalactosylated N-glycans in serum (sG0/G1) with therapy does not distinguish
methotrexate (MTX) and TNF inhibition. Relationship between therapy and the correlation between clinical improvement and changes in
sG0/G1 for patients in whom MTX or TNF inhibition was the only new therapeutic agent in the interval between t = 0 and t = 3 months. TNF
inhibitor (n = 79) (Autoimmune Biomarkers Collaborative Network and Nested I), Spearman’s r = 0.34; MTX (n = 19) (Nested I only), Spearman’s
r = 0.16 (P = 0.56 vs TNF inhibitor group).
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perhaps together with other clinical or genetic markers,
might still uncover associations of diagnostic or thera-
peutic importance in RA. Because patients receiving
MTX alone were enrolled only in the smaller cohort
(Nested I), relatively few were available for analysis, thus
limiting the power of our data to exclude definitively a
difference between MTX and TNF inhibitors with
respect to the correlation between changes in G0/G1 and
in DAS (Figure 4).
Conclusions
These results represent the first exploration of the
potential utility of IgG glycosylation as a predictor of
therapeutic response in RA. Our results confirm that
hypogalactosylation of IgG (assessed in our present
study via the proxy measure sG0/G1) is prominent in
patients with RA and improves with therapy, but they
neither support the use of the sG0/G1 index as a guide
to choosing between MTX and TNF inhibitors nor sug-
gest a differential effect of these agents on IgG galacto-
sylation. However, we have identified for the first time
an association between ACPA positivity and aberrant
IgG glycosylation, further extending the understanding
the relationship between antibody glycans and RA.
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